Bristol-Myers Squibb to sell stake in diabetes alliance to AstraZeneca

It was announced today that AstraZeneca has agreed to acquire Bristol-Myers Squibb’s stake in the companies’ diabetes joint venture.

AstraZeneca is to make an upfront payment of $2.7 billion to Bristol-Myers Squibb, with milestone payments of up to $1.4 billion and royalty payments based on net sales up until 2025 may make payments up to $225m when certain assets are subsequently transferred.

This agreement will allow us to further evolve our business model as a leading specialty BioPharma company and increase resources behind the opportunities that drive the greatest long-term value for patients, our company and our shareholders. Today’s announcement puts the diabetes franchise in the capable hands of AstraZeneca and allows us to move to a more simplified operating model consistent with our pipeline and portfolio.

Lamberto Andreotti, chief executive officer, Bristol-Myers Squibb.

“…the deal reinforces AstraZeneca’s long-term commitment to diabetes, a core strategic area for us and an important platform for returning…to growth.

Pascal Soriot, CEO of AstraZeneca

 

Related news:

AstraZeneca to buy Bristol-Myers Squibb’s stake in diabetes alliance for up to $4.3 billion (FirstWord Pharma)

AstraZeneca to buy Bristol out of diabetes venture for up to $4.1 billion (Reuters)

Reference links:

BMS press release

Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.